NEWS - 2010

Print PDF

Interface Biologics – Fresenius Medical Care Sign License Agreement


Toronto-- July 20, 2010 --Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, is pleased to announce the signing of an evaluation and exclusive license option agreement with Fresenius Medical Care, the world's largest integrated provider of dialysis products and services.

MORE

Print PDF

Interface Biologics Inc’s Chief Scientific Officer Wins Julia Levy Award

Toronto, Canada, March 5, 2010 - For Immediate Release

Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the safety and effectiveness of medical devices, is proud to announce that one of it's co-founders

MORE